ASCEND long-term follow up
We plan to collect information from electronic records of NHS Healthcare data for those who participated in ASCEND until 2037. This will help us to see whether there are benefits or harms of aspirin on cancers, heart failure and dementia that we didn’t see during ASCEND because the follow-up duration was too short.
The results of analyses conducted approximately five years after the trial ended are expected to be available by late 2025. Additional analyses will be done over the next few years. The main findings of these analyses will be presented here.
documentation
Patient information leaflet (link to webpage)
Heart failure-ASCEND data analysis plan (link to webpage)
End of participation information leaflet (link to webpage)
Screening questionnaire with patient consent form (pdf)
Blood and urine sampling consent form (pdf)
Randomisation questionnaire (pdf)
Final follow-up questionnaire (pdf)